SAN MATEO, Calif., July 20, 2011 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) today announced the enrollment of the first patient in a Phase 1 trial to evaluate the safety, activity and pharmacokinetics of Marqibo® (vincristine sulfate liposomes injection) in children and adolescents with relapsed or refractory cancer being conducted by the Pediatric Branch of the National Cancer Institute (NCI). http://clinicaltrials.gov/ct2/show/NCT01222780
